Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is listed today as Perspective Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $87 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jan 2024 | $21 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Feb 2023 | $55 M | Private placement after listing | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Perspective Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).
SEC Form D · Mar 2024
The industry group it chose in its notices: Other Health Care.
SEC Form D · Mar 2024
That is all the official record says: Perspective Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Perspective Therapeutics, Inc. are on record.
Investors#
No investor of Perspective Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Perspective Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$33 M9.79%
- TCG Crossover Management, LLC$22 M6.55%
- Millennium Management LLC$17 M5.13%
- Avidity Partners Management LP$17 M5.02%
- Vanguard Capital Management LLC$12 M3.65%
- Affinity Asset Advisors, LLC$11 M3.30%
- Citadel Advisors LLC$11 M3.29%
- Spruce Street Capital LP$10 M3.06%
- Two Sigma Investments, LP$8 M2.48%
- ADAR1 Capital Management, LLC$7 M2.17%
- Nantahala Capital Management, LLC$7 M2.06%
- Geode Capital Management, LLC$6 M1.69%
- State Street Corp$6 M1.68%
- Nicholson Wealth Management Group, LLC$4 M1.34%
- Marshall Wace, LLP$4 M1.23%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Johan (Thijs) Spoor | Executive officer | Mar 2024 |
| Jonathan Hunt | Executive officer | Mar 2024 |
| Mark Austin | Executive officer | Mar 2024 |
| Markus Puhlmann | Executive officer | Mar 2024 |
| Jennifer Streeter | Executive officer | Feb 2023 |
| Frank Morich | Director | Mar 2024 |
| Heidi Henson | Director | Mar 2024 |
| Johan (Thijs) Spoor | Director | Mar 2024 |
| Lori Woods | Director | Mar 2024 |
| Robert Williamson III | Director | Mar 2024 |
| Michael McCormick | Director | Feb 2023 |
Went public since 2013. Its SEC number is that of a company listed on a stock exchange.